Resting tremor in Parkinson disease: A negative predictor of levodopa-induced dyskinesia

Archives of Neurology

Volumn 68, Issue 8, 2011, Pages 1037-1039

  Kipfer, Stefan ^a   Stephan, Marianne A ^a,b   Schüpbach, W M Michael ^a   Ballinari, Pietro ^a   Kaelin Lang, Alain ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; FEMALE; HUMAN; INATTENTION TREMOR; LEVODOPA INDUCED DYSKINESIA; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; TERTIARY HEALTH CARE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; COHORT STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREMOR;

EID: 80051575595     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.147     Document Type: Article

References (18)

1. Fahn S, Oakes D, Shoulson I, et al Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-2508.
2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442.
3. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756-1760. (Pubitemid 44925085)
4. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006;5(4):355-363.
5. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol. 2000;47(4) (suppl 1):S2-S11. (Pubitemid 30192005)
6. Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. Arch Neurol. 2006;63(3):354-357.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
8. Schwab R, England A. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease. Edinburgh, Scotland: Livingstone; 1969:152-158.
9. Fahn S, Elton RL. The Unified Parkinson's Disease Rating Scale. Vol 2. Florham Park, NY: Macmillan Health Care Information; 1987.
10. Schüpbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005; 76(12):1640-1644. (Pubitemid 41697626)
11. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology. 2004; 62(2):201-207. (Pubitemid 38167125)
12. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons Inc; 2000.
13. Fishman PS. Paradoxical aspects of parkinsonian tremor. Mov Disord. 2008;23 (2):168-173. (Pubitemid 351311543)
14. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology. 2009;73(3):206- 212.
15. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. 2003;18(suppl 7):S43-S51. (Pubitemid 37336928)
16. Jansen EN. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand. 1994;89(4):262-265. (Pubitemid 24159038)
17. Reichmann H. Budipine in Parkinson's tremor. J Neurol Sci. 2006;248(1-2):53-55. (Pubitemid 44647313)
18. Blahak C, Wöhrle JC, Capelle HH, et al. Tremor reduction by subthalamic nucleus stimulation and medication in advanced Parkinson's disease. J Neurol. 2007; 254(2):169-178. (Pubitemid 46356048)